No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Medical - Specialties
Sysmex Corporation, headquartered in Kobe, Japan, and established in 1968 (originally known as TOA Medical Electronics Co., Ltd. until its rebranding in October 1998), specializes in the development, manufacturing, and global distribution of advanced diagnostic instrumentation, chemical reagents, and associated software. Its comprehensive product portfolio addresses various diagnostic needs. In hematology, it offers instruments for both three-part and five-part white blood cell differentiation, alongside efficient transport systems designed for high-volume laboratory testing. For urinalysis, the company provides systems capable of analyzing urine formed sediment. Its offerings extend to automated immunochemistry systems, which are adept at performing assays with minute sample quantities, complemented by reagents for detecting infectious diseases and tumor markers. Sysmex also manufactures flow cytometers, crucial for the analysis involved in diagnosing conditions such as leukemia, malignant lymphoma, and HIV/AIDS. Beyond these core areas, the company is deeply involved in oncology diagnostics, developing systems for detecting cancer lymph node metastasis and cancer genome profiling, as well as offering cytogenetic testing and specialized lab assay services. Sysmex also contributes to digital medicine through the development and sale of software for diagnostic information systems, alongside the creation, operation, and maintenance of IT solutions, platforms, and applications in this field. Its activities further encompass the development and sale of nucleic acid analogs, the full lifecycle management (marketing, development, design, manufacture, sale, and after-sales support) of medical robots, and the distribution and post-sales support for medical devices and reagents used in biotechnology, medical technology, and molecular cell analysis. Sysmex serves a diverse client base, including national, public, and private hospitals, universities, research institutes, and other medical facilities. With a robust international presence, the company exports its products to approximately 190 countries worldwide. Demonstrating its commitment to innovation, Sysmex Corporation maintains a strategic alliance with QIAGEN N.V. for the collaborative development and commercialization of cancer companion diagnostics utilizing Plasma-Safe-SeqS technology.
www.sysmex.co.jpNo one on the platform currently holds 6869.T.
No tracked institution reports a position in 6869.T as of their last filing.
No one on the platform has traded 6869.T yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 9.1% | 13.1% | 16.5% | — | — | — |
| Rev. Growth % | -1.7% | 10.4% | ||||
| Profit Margin % | 7.1% | 10.3% | 11.8% | |||
| Free Cash Flow Margin % | 8.2% | 10.6% | 11.2% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2027 | $545.9B | +9.6% | $67.57 | $58.94–$79.77 | — | 13 |
| 2028 | $575.8B | +5.5% | $83.50 | $67.96–$121.84 | — | 15 |
| 2029 | $607.9B | +5.6% | $97.94 | $73.93–$135.16 | — | 14 |
| 2030 | $649.2B | +6.8% | $111.66 | $102.31–$120.91 | — | 7 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 4 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-07 | $9.00 | $14.17 | +57.4% |
| 2026-05-14 | $5.94 | $2.84 | -52.2% |
| 2026-02-12 | $21.84 | $23.55 | +7.8% |
| 2025-11-05 | $24.74 | $23.20 | -6.2% |
| 2025-08-06 | $17.15 | $7.30 | -57.4% |
| 2025-05-14 | $23.09 | $17.72 | -23.3% |
| 2025-02-12 | $22.40 | $26.65 | +19.0% |
| 2024-11-06 | $22.70 |
| $24.01 |
| +5.8% |
| +1.30% |
| $225.9B |
| — |
| 4151.TKyowa Kirin Co., Ltd. | $2225.50 | +1.55% | $1.17T | — |
| 4506.TSumitomo Pharma Co., Ltd. | $1567.50 | +2.65% | $703.2B | — |
Source: Financial Modeling Prep · peers by sector/industry